Page header

Recommendation of the President – Paediatric Seravit

On 8 January, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 2/2026 on the validity of granting approval for the reimbursement of the product Paediatric Seravit for the indications: very long-chain acidoxia (VLCAD) and isovaleric aciduria

Publication in Public Information Bulletin (BIP) >>